Treasure Global to Report Second Quarter Fiscal Year 2023 6-02-2023, 18:39

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00

Amlan® International Expands in Southern Vietnam with New Distribution Partner, Saigon Nutrition Corporation 1-12-2023, 04:00